Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity
作者:Jean Lee、Anthony J. Chubb、Edelmiro Moman、Brian M. McLoughlin、Caroline T. Sharkey、John G. Kelly、Kevin B. Nolan、Marc Devocelle、Desmond J. Fitzgerald
DOI:10.1039/b505525c
日期:——
Currently available non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin are directed at the cyclooxygenase (COX) site, but not the peroxidase (POX) activity of prostaglandin H2 synthase (PGHS). They are thus unable to inhibit the free-radical induced tissue injury associated with PGHS peroxidase activity, which can occur independently of the COX site. A lead compound, anthranilic hydroxamic
当前可用的非甾体抗炎药(NSAID)(例如阿司匹林)针对的是环氧合酶(COX)位点,而不针对前列腺素H2合酶(PGHS)的过氧化物酶(POX)活性。因此,它们不能抑制与PGHS过氧化物酶活性相关的自由基诱导的组织损伤,而损伤可能独立于COX部位而发生。发现先导化合物邻氨基苯甲酸异羟肟酸(AHA)具有显着的PGHS-POX抑制活性(IC50 = 72 microM)。为了定义抑制PGHS-POX的关键参数,我们研究了使用固相合成方法从其酸前体合成的29种AHA衍生物。体外分析表明3,5-二碘邻氨基苯甲酸异羟肟酸(IC50 = 7 microM)的抑制作用提高了十倍。